시장보고서
상품코드
1766395

STI 및 질염 PCR 검사 시장 규모, 점유율, 동향, 산업 분석 보고서 : 병태별(성감염증, 질염), 검사 유형별, 최종 용도별, 지역별 - 시장 예측(2025-2034년)

STI and Vaginitis PCR Testing Market Size, Share, Trends, & Industry Analysis Report By Condition [Sexually Transmitted Infections (STIs) and Vaginal Infections], By Test Type, By End Use, and By Region - Market Forecast, 2025-2034

발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 125 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면, 세계 STI 및 질염 PCR 검사 시장 규모는 2034년까지 15억 7,843만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 인사이트와 향후 시장 성장에 대한 분석을 제공합니다.

STI 및 질염 PCR 검사 시장은 STI 및 다양한 유형의 질 감염에 대한 병원체 특이적 검사를 위해 중합효소 연쇄 반응(PCR) 기술을 이용한 고급 진단을 수행하는 데 초점을 맞추고 있습니다. PCR 검사는 높은 민감도와 특이성, 그리고 아무리 미량이라도 원인균의 유전물질을 정확하게 포착하는 능력으로 다른 검사법에서는 찾아볼 수 없는 독특한 검사법입니다. 다른 검사법에는 없는 독특한 것입니다. 이러한 정확성은 신속하고 정확한 진단과 질병의 진행 및 추가 감염의 필요성에 대처하기 위한 강력하고 정확한 치료 계획을 수립하는 데 필수적입니다.

이 분야의 검사에 대한 기대는 여러 가지 이유로 특히 낙관적입니다. 지역적으로 STI와 질염의 유병률이 증가함에 따라 정확한 진단에 대한 수요가 증가하고 있습니다. 멀티플렉스 PCR 분석법 개발과 같은 분자진단 도구의 개발도 이 분야의 성장을 가속화하고 있습니다. 단일 샘플에서 여러 병원체를 검출할 수 있는 능력은 효율성을 높이고 임상의에게 진단 정보를 제공합니다. 또한, 대중의 인식과 적극적인 검진 캠페인은 집단 검진의 강도를 높이고 있으며, 이는 명확하게 정의된 성 및 생식 건강을 향한 고무적인 추세입니다. 이러한 변화에는 정확하고 신뢰할 수 있는 진단 도구가 필요하며, 이를 통해 목적의식을 가지고 전략적으로 문자에 접근할 수 있도록 해야 합니다.

STI 및 질염 PCR 검사 시장 보고서 하이라이트

질환별로는 성병(STI) 분야가 2024년 가장 큰 비중을 차지했습니다. 이는 다양한 STI의 전 세계 유병률이 지속적으로 높고, 대부분 무증상이며, 광범위한 스크리닝 및 공중 보건 관리를 위해 PCR과 같은 정확하고 민감한 진단 도구가 매우 중요하기 때문입니다.

검사 유형별로는 STI PCR 패널 부문이 2024년 시장을 주도했습니다. 이러한 우위는 주로 종합적인 진단 및 치료 지침에 필수적인 멀티플렉스 패널을 통한 광범위한 성병 병원체의 정확하고 민감한 동시 검출에 대한 중요한 요구사항에 기인합니다.

최종 용도별로는 진단 실험실 부문이 2024년 가장 큰 점유율을 차지했습니다. 이는 전문 인프라, 높은 처리량, 다양한 의료 환경에서 대량의 복잡한 분자진단 테스트를 처리하는 데 필요한 전문 지식이 필요하기 때문입니다.

지역별로는 북미가 STI 및 질염 PCR 검사 시장에서 가장 큰 점유율을 차지하고 있습니다. 이는 주로 탄탄한 의료 인프라, 성 건강에 대한 높은 인식, PCR 기반 분석을 포함한 첨단 진단 기술의 조기 도입에 기인합니다. 아시아태평양의 STI 및 질염 PCR 검사 시장은 예측 기간 동안 상당한 성장률을 보일 것으로 예상됩니다. 이러한 성장의 주요 요인은 의료 인프라 개선, 가처분 소득 증가, 중국 및 인도와 같은 국가에서 성 및 생식 건강에 대한 인식이 높아졌기 때문입니다.

이 시장의 주요 기업으로는 Hologic, Inc., BD (Becton, Dickinson and Company), bioMerieux, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott Laboratories, Qiagen, OraSure Technologies, and SpeeDx Pty Ltd. 등이 있습니다. 또한, Cepheid (Danaher) and Luminex Corporation (DiaSorin S.p.A.)과 같이 더 큰 모회사 산하에 운영되는 주요 기업도 있습니다.

목차

제1장 소개

제2장 주요 요약

제3장 조사 방법

제4장 세계의 STI 및 질염 PCR 검사 시장 인사이트

  • 시장 현황
  • STI 및 질염 PCR 검사 시장 역학
    • 성장 촉진요인과 기회
      • 성감염증과 질염 만연
      • 분자진단의 기술 진보
    • 성장 억제요인과 과제
      • 고비용과 인프라 장벽
  • PESTEL 분석
  • STI 및 질염 PCR 검사 시장 애플리케이션 동향
  • 밸류체인 분석
  • COVID-19의 영향 분석

제5장 세계의 STI 및 질염 PCR 검사 시장 : 병태별

  • 주요 조사 결과
  • 소개
  • 성감염증(STI)
  • 질감염증

제6장 세계의 STI 및 질염 PCR 검사 시장 : 검사 유형별

  • 주요 조사 결과
  • 소개
  • STI PCR 패널
  • 질염 PCR 패널

제7장 세계의 STI 및 질염 PCR 검사 시장 : 최종 용도별

  • 주요 조사 결과
  • 소개
  • 병원과 진료소
  • 진단 검사실
  • 홈케어/재택 검사
  • 기타

제8장 세계의 STI 및 질염 PCR 검사 시장 : 지역별

  • 주요 조사 결과
  • 소개
    • STI 및 질염 PCR 검사 시장 평가 : 지역별, 2020-2034년
  • 북미
    • 북미 : 병태별, 2020-2034년
    • 북미 : 검사 유형별, 2020-2034년
    • 북미 : 최종 용도별, 2020-2034년
    • 미국
    • 캐나다
  • 유럽
    • 유럽 : 병태별, 2020-2034년
    • 유럽 : 검사 유형별, 2020-2034년
    • 유럽 : 최종 용도별, 2020-2034년
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
    • 기타 유럽
  • 아시아태평양
    • 아시아태평양 : 병태별, 2020-2034년
    • 아시아태평양 : 검사 유형별, 2020-2034년
    • 아시아태평양 : 최종 용도별, 2020-2034년
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 중동 및 아프리카 : 병태별, 2020-2034년
    • 중동 및 아프리카 : 검사 유형별, 2020-2034년
    • 중동 및 아프리카 : 최종 용도별, 2020-2034년
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 남아프리카공화국
    • 기타 중동 및 아프리카
  • 라틴아메리카
    • 라틴아메리카 : 병태별, 2020-2034년
    • 라틴아메리카 : 검사 유형별, 2020-2034년
    • 라틴아메리카 : 최종 용도별, 2020-2034년
    • 멕시코
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카

제9장 경쟁 구도

  • 확대와 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제10장 기업 개요

  • Abbott Laboratories
  • BD(Becton, Dickinson and Company)
  • bioMerieux
  • Cepheid(Danaher)
  • F. Hoffmann-La Roche Ltd
  • Hologic, Inc.
  • Luminex Corporation(DiaSorin S.p. A.)
  • OraSure Technologies
  • Qiagen
  • SpeeDx Pty Ltd
  • Thermo Fisher Scientific Inc.
ksm 25.07.17

The global STI and vaginitis PCR testing market size is expected to reach USD 1,578.43 million by 2034, according to a new study by Polaris Market Research. The report "STI and Vaginitis PCR Testing Size, Share, Trends & Industry Analysis Report: By Condition [Sexually Transmitted Infections (STIs) and Vaginal Infections], By Test Type, By End Use, and By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The STI and vaginitis PCR testing market focuses on the implementation of advanced diagnostics using polymerase chain reaction (PCR) technology for pathogen specific testing of STIs and different types of vaginal infections. These infections encompass common sexually transmitted infections (STIs) such as chlamydia, gonorrhea, and trichomoniasis, alongside vaginal infections such as bacterial vaginosis and vulvovaginal candidiasis. PCR testing is unique among other testing methods due to its high sensitivity and specificity, and its ability to accurately capture the genetic material of causative organisms, no matter how minute the quantities are. This level of precision is essential for prompt and accurate diagnosis and an intense and precise treatment plan that addresses disease progression and further transmission needs.

The expectations related to this area of testing are particularly optimistic for multiple reasons. The rising prevalence of STIs and vaginitis regionally augments the demand for accurate diagnosis. The advancement in molecular diagnostic tools, as in the case of multiplex PCR assay development, is also accelerating growth in this area. The ability to detect multiple pathogens from a single sample increases both efficiency and provides enhanced diagnostic information for clinicians. Moreover, public awareness and proactive screening campaigns heighten population testing intensity, which is an encouraging trend directed toward explicitly defined sexual and reproductive health. Such changes necessitate accurate and reliable tools for diagnosis and, thereby, purposeful and strategic toward letter accessibility.

STI and Vaginitis PCR Testing Market Report Highlights:

By condition, the sexually transmitted infections (STIs) segment held a larger share in 2024, driven by the persistent high global prevalence of various STIs, many of which are asymptomatic, and the crucial need for accurate, sensitive diagnostic tools such as PCR for widespread screening and public health management.

By test type, the STI PCR panels segment dominated the market in 2024. The dominance is primarily attributed to the critical requirement for accurate and sensitive detection of a broad range of sexually transmitted pathogens, often simultaneously through multiplex panels, which are essential for comprehensive diagnosis and treatment guidance.

By end use, the diagnostic laboratories segment held the largest share in 2024, owing to their specialized infrastructure, high-throughput capabilities, and the expertise necessary for processing a large volume of complex molecular diagnostic tests from various healthcare settings.

By region, North America holds a substantial share of the STI and vaginitis PCR testing market. This is largely attributed to the robust healthcare infrastructure, high awareness regarding sexual health, and the early adoption of advanced diagnostic technologies, including PCR-based assays. The Asia Pacific STI and vaginitis PCR testing market is anticipated to exhibit a significant growth rate during the forecast period. This growth is primarily fueled by improving healthcare infrastructure, increasing disposable incomes, and a rising awareness about sexual and reproductive health in countries such as China and India.

A few key players in the market include Hologic, Inc.; BD (Becton, Dickinson and Company); bioMerieux; F. Hoffmann-La Roche Ltd; Thermo Fisher Scientific Inc.; Abbott Laboratories; Qiagen; OraSure Technologies; and SpeeDx Pty Ltd. Additionally, some key entities operate under larger parent organizations, such as Cepheid (Danaher) and Luminex Corporation (DiaSorin S.p.A.).

Polaris Market Research has segmented the STI and vaginitis PCR testing market report on the basis of condition, test type, end use, and region:

By Condition Outlook (Revenue - USD Million, 2020-2034)

Sexually Transmitted Infections (STIs)

Chlamydia

Gonorrhea

Trichomoniasis

Herpes Simplex Virus (HSV-1 & HSV-2)

Human Papillomavirus (HPV)

Syphilis

Other

Vaginal Infections

Bacterial Vaginosis

Vulvovaginal Candidiasis

Other

By Test Type Outlook (Revenue - USD Million, 2020-2034)

STI PCR Panels

Vaginitis PCR Panels

By End Use Outlook (Revenue - USD Million, 2020-2034)

Hospitals & Clinics

Diagnostic Laboratories

Homecare/At-home Testing

Others

By Regional Outlook (Revenue - USD Million, 2020-2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Source
    • 3.2.1. Primary Source
    • 3.2.2. Secondary Source

4. Global STI and Vaginitis PCR Testing Market Insights

  • 4.1. STI and Vaginitis PCR Testing Market - Market Snapshot
  • 4.2. STI and Vaginitis PCR Testing Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Prevalence of STIs and Vaginitis
      • 4.2.1.2. Technological Advancements in Molecular Diagnostics
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost and infrastructure barriers
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. STI and Vaginitis PCR Testing Market Application Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global STI and Vaginitis PCR Testing Market, by Condition

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
  • 5.3. Sexually Transmitted Infections (STIs)
    • 5.3.1. Global STI and Vaginitis PCR Testing Market, by Sexually Transmitted Infections (STIs), by Region, 2020-2034 (USD Million)
    • 5.3.2. Chlamydia
    • 5.3.3. Gonorrhea
    • 5.3.4. Trichomoniasis
    • 5.3.5. Herpes Simplex Virus (HSV-1 & HSV-2)
    • 5.3.6. Human Papillomavirus (HPV)
    • 5.3.7. Syphilis
    • 5.3.8. Other
  • 5.4. Vaginal Infections
    • 5.4.1. Global STI and Vaginitis PCR Testing Market, by Vaginal Infections, by Region, 2020-2034 (USD Million)
    • 5.4.2. Bacterial Vaginosis
    • 5.4.3. Vulvovaginal Candidiasis
    • 5.4.4. Other

6. Global STI and Vaginitis PCR Testing Market, by Test Type

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
  • 6.3. STI PCR Panels
    • 6.3.1. Global STI and Vaginitis PCR Testing Market, by STI PCR Panels, by Region, 2020-2034 (USD Million)
  • 6.4. Vaginitis PCR Panels
    • 6.4.1. Global STI and Vaginitis PCR Testing Market, by Vaginitis PCR Panels, by Region, 2020-2034 (USD Million)

7. Global STI and Vaginitis PCR Testing Market, by End Use

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
  • 7.3. Hospitals & Clinics
    • 7.3.1. Global STI and Vaginitis PCR Testing Market, by Hospitals & Clinics, by Region, 2020-2034 (USD Million)
  • 7.4. Diagnostic Laboratories
    • 7.4.1. Global STI and Vaginitis PCR Testing Market, by Diagnostic Laboratories, by Region, 2020-2034 (USD Million)
  • 7.5. Homecare/At-home Testing
    • 7.5.1. Global STI and Vaginitis PCR Testing Market, by Homecare/At-home Testing, by Region, 2020-2034 (USD Million)
  • 7.6. Others
    • 7.6.1. Global STI and Vaginitis PCR Testing Market, by Others, by Region, 2020-2034 (USD Million)

8. Global STI and Vaginitis PCR Testing Market, by Geography

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. STI and Vaginitis PCR Testing Market Assessment, By Geography, 2020-2034 (USD Million)
  • 8.3. STI and Vaginitis PCR Testing Market - North America
    • 8.3.1. North America: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
    • 8.3.2. North America: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
    • 8.3.3. North America: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.3.4. STI and Vaginitis PCR Testing Market - U.S.
      • 8.3.4.1. U.S.: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.3.4.2. U.S.: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.3.4.3. U.S.: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.3.5. STI and Vaginitis PCR Testing Market - Canada
      • 8.3.5.1. Canada: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.3.5.2. Canada: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.3.5.3. Canada: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
  • 8.4. STI and Vaginitis PCR Testing Market - Europe
    • 8.4.1. Europe: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
    • 8.4.2. Europe: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
    • 8.4.3. Europe: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.4.4. STI and Vaginitis PCR Testing Market - UK
      • 8.4.4.1. UK: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.4.4.2. UK: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.4.4.3. UK: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.4.5. STI and Vaginitis PCR Testing Market - France
      • 8.4.5.1. France: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.4.5.2. France: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.4.5.3. France: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.4.6. STI and Vaginitis PCR Testing Market - Germany
      • 8.4.6.1. Germany: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.4.6.2. Germany: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.4.6.3. Germany: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.4.7. STI and Vaginitis PCR Testing Market - Italy
      • 8.4.7.1. Italy: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.4.7.2. Italy: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.4.7.3. Italy: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.4.8. STI and Vaginitis PCR Testing Market - Spain
      • 8.4.8.1. Spain: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.4.8.2. Spain: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.4.8.3. Spain: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.4.9. STI and Vaginitis PCR Testing Market - Netherlands
      • 8.4.9.1. Netherlands: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.4.9.2. Netherlands: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.4.9.3. Netherlands: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.4.10. STI and Vaginitis PCR Testing Market - Russia
      • 8.4.10.1. Russia: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.4.10.2. Russia: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.4.10.3. Russia: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.4.11. STI and Vaginitis PCR Testing Market - Rest of Europe
      • 8.4.11.1. Rest of Europe: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.4.11.2. Rest of Europe: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.4.11.3. Rest of Europe: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
  • 8.5. STI and Vaginitis PCR Testing Market - Asia Pacific
    • 8.5.1. Asia Pacific: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
    • 8.5.2. Asia Pacific: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
    • 8.5.3. Asia Pacific: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.5.4. STI and Vaginitis PCR Testing Market - China
      • 8.5.4.1. China: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.5.4.2. China: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.5.4.3. China: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.5.5. STI and Vaginitis PCR Testing Market - India
      • 8.5.5.1. India: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.5.5.2. India: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.5.5.3. India: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.5.6. STI and Vaginitis PCR Testing Market - Malaysia
      • 8.5.6.1. Malaysia: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.5.6.2. Malaysia: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.5.6.3. Malaysia: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.5.7. STI and Vaginitis PCR Testing Market - Japan
      • 8.5.7.1. Japan: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.5.7.2. Japan: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.5.7.3. Japan: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.5.8. STI and Vaginitis PCR Testing Market - Indonesia
      • 8.5.8.1. Indonesia: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.5.8.2. Indonesia: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.5.8.3. Indonesia: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.5.9. STI and Vaginitis PCR Testing Market - South Korea
      • 8.5.9.1. South Korea: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.5.9.2. South Korea: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.5.9.3. South Korea: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.5.10. STI and Vaginitis PCR Testing Market - Australia
      • 8.5.10.1. Australia: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.5.10.2. Australia: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.5.10.3. Australia: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.5.11. STI and Vaginitis PCR Testing Market - Rest of Asia Pacific
      • 8.5.11.1. Rest of Asia Pacific: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.5.11.2. Rest of Asia Pacific: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.5.11.3. Rest of Asia Pacific: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
  • 8.6. STI and Vaginitis PCR Testing Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
    • 8.6.2. Middle East & Africa: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
    • 8.6.3. Middle East & Africa: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.6.4. STI and Vaginitis PCR Testing Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.6.4.2. Saudi Arabia: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.6.4.3. Saudi Arabia: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.6.5. STI and Vaginitis PCR Testing Market - UAE
      • 8.6.5.1. UAE: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.6.5.2. UAE: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.6.5.3. UAE: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.6.6. STI and Vaginitis PCR Testing Market - Israel
      • 8.6.6.1. Israel: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.6.6.2. Israel: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.6.6.3. Israel: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.6.7. STI and Vaginitis PCR Testing Market - South Africa
      • 8.6.7.1. South Africa: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.6.7.2. South Africa: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.6.7.3. South Africa: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.6.8. STI and Vaginitis PCR Testing Market - Rest of Middle East & Africa
      • 8.6.8.1. Rest of Middle East & Africa: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.6.8.2. Rest of Middle East & Africa: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.6.8.3. Rest of Middle East & Africa: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
  • 8.7. STI and Vaginitis PCR Testing Market - Latin America
    • 8.7.1. Latin America: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
    • 8.7.2. Latin America: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
    • 8.7.3. Latin America: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.7.4. STI and Vaginitis PCR Testing Market - Mexico
      • 8.7.4.1. Mexico: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.7.4.2. Mexico: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.7.4.3. Mexico: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.7.5. STI and Vaginitis PCR Testing Market - Brazil
      • 8.7.5.1. Brazil: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.7.5.2. Brazil: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.7.5.3. Brazil: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.7.6. STI and Vaginitis PCR Testing Market - Argentina
      • 8.7.6.1. Argentina: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.7.6.2. Argentina: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.7.6.3. Argentina: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)
    • 8.7.7. STI and Vaginitis PCR Testing Market - Rest of Latin America
      • 8.7.7.1. Rest of Latin America: STI and Vaginitis PCR Testing Market, by Condition, 2020-2034 (USD Million)
      • 8.7.7.2. Rest of Latin America: STI and Vaginitis PCR Testing Market, by Test Type, 2020-2034 (USD Million)
      • 8.7.7.3. Rest of Latin America: STI and Vaginitis PCR Testing Market, by End Use, 2020-2034 (USD Million)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Abbott Laboratories
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Recent Development
  • 10.2. BD (Becton, Dickinson and Company)
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Benchmarking
    • 10.2.4. Recent Development
  • 10.3. bioMerieux
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Cepheid (Danaher)
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Benchmarking
    • 10.4.4. Recent Development
  • 10.5. F. Hoffmann-La Roche Ltd
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Hologic, Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Benchmarking
    • 10.6.4. Recent Development
  • 10.7. Luminex Corporation (DiaSorin S.p. A.)
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Benchmarking
    • 10.7.4. Recent Development
  • 10.8. OraSure Technologies
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Qiagen
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Benchmarking
    • 10.9.4. Recent Development
  • 10.10. SpeeDx Pty Ltd
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Benchmarking
    • 10.10.4. Recent Development
  • 10.11. Thermo Fisher Scientific Inc.
    • 10.11.1. Company Overview
    • 10.11.2. Financial Performance
    • 10.11.3. Product Benchmarking
    • 10.11.4. Recent Development
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제